Role of Pharmaceutical Softwares in Enhancing Quality, Safety, And Compliance: A Systematic Review

Abstract

Drug discovery is one of the most challenging and resource-intensive processes in pharmaceutical research, often hindered by high attrition rates, extended timelines, and escalating costs. The integration of pharmaceutical software has revolutionized this field by enabling faster, more accurate, and cost-effective strategies across different stages of development. This review provides an overview of the role of computational tools in drug discovery, highlighting their application in target identification, molecular docking, QSAR-based lead optimization, and ADMET prediction. Widely used platforms such as AutoDock, Schrödinger Glide, Discovery Studio, SwissADME, and pkCSM have become essential for modeling molecular interactions, predicting pharmacokinetic properties, and prioritizing drug candidates. These in silico approaches significantly reduce experimental workload and improve the probability of clinical success, thereby accelerating the overall process of drug development. However, challenges remain in terms of software licensing costs, computational limitations, and the need for skilled expertise. Future directions are focused on the integration of artificial intelligence and machine learning, which promise to enhance prediction accuracy and open new horizons in personalized medicine. Overall, pharmaceutical software is reshaping the landscape of modern drug discovery and development.

Introduction

Technology—especially computers—has become essential in the field of pharmacy. Modern pharmaceutical education and practice rely heavily on computer skills, as pharmacists use software for patient care, research, and data management. With rapid advancements in hardware and software, computer literacy is now a key part of pharmacy curricula worldwide.

In the pharmaceutical industry, specialized software systems support every stage of drug development—from discovering new molecules to manufacturing, quality control, clinical trials, regulatory submissions, and post-marketing safety monitoring. Tools such as EDC, CTMS, LIMS, and pharmacovigilance software help companies handle large datasets, improve accuracy, and meet global regulatory standards like those of the FDA and EMA.

Technologies such as artificial intelligence (AI), machine learning (ML), and automation are increasingly used to accelerate research, predict drug behavior, monitor manufacturing processes, and support smarter decision-making. Despite these benefits, challenges remain, including data security, system integration, privacy concerns, and strict validation requirements for regulatory compliance.

Pharmaceutical software is broadly categorized into different types, including:

• Drug discovery software (AutoDock, Schrodinger, ChemDraw) for molecular modeling and virtual screening.

• Formulation development tools (Design Expert, GastroPlus) to optimize dosage forms and predict bioavailability.

• Manufacturing and production systems (MES, ERP) for GMP-compliant operations and batch monitoring.

• Quality control and assurance software (LIMS, Empower, MasterControl) for laboratory testing, documentation, and compliance.

• Regulatory software (eCTD Manager, PharmaReady) for document submission.

• Pharmacovigilance tools (Argus Safety, VigiBase) to track adverse drug reactions.

• Clinical data management systems (Medidata Rave, Oracle Clinical) for secure clinical trial data handling.

• AI-based platforms for predictive modeling and faster drug discovery.

Examples like AutoDock aid in molecular docking and virtual screening, while GastroPlus simulates drug absorption and pharmacokinetics using advanced PBPK and PBBM models.

Integrating AI with pharmaceutical software has transformed the industry by improving prediction accuracy, reducing development time, enhancing manufacturing efficiency, automating regulatory workflows, and strengthening pharmacovigilance systems. However, challenges such as algorithm transparency, ethics, and regulatory compliance still need attention.

Overall, pharmaceutical software is now a fundamental driver of innovation, quality, and safety across the drug development lifecycle, and AI is shaping the future of pharmaceutical research, manufacturing, and healthcare delivery.

Conclusion

In summary, software has become a vital component of the pharmaceutical industry, fundamentally transforming its operations. The integration of software solutions has enhanced productivity, efficiency, and accuracy across all stages of the pharmaceutical process—from drug discovery and development to clinical trials and regulatory compliance. Key software systems, such as Electronic Data Capture (EDC), Clinical Trial Management Systems (CTMS), Pharmacovigilance Systems, and Electronic Document Management Systems (EDMS), enable companies to manage data effectively, streamline workflows, maintain compliance, and support informed decision-making. As technology continues to advance and the demand for personalized medicine increases, the role of software in the pharmaceutical sector is expected to expand further, driving continued innovation and operational improvement.

References

[1] Wang L. Computer-simulated pharmacology experiments for undergraduate pharmacy students: experience from an Australian university. Indian J Pharmacol. 2001; 33(4):280-2 [2] Upadhyay P. The Role of “Verification and Validation in System Development Life Cycle” IOSR Journal of Computer Engineering 5(1), sep-oct 2012, 17-20. 2. Sanika R. Joshi, Vijay R. Salunkhe. Overview on Software Used in Pharma Industry. Int. J. Pharm. Sci. Rev. Res., 61(1), March - April 2020; Article No. 09, Pages: 52-58, ISSN 0976 – 044X [3] Sanika R. Joshi, Vijay R. Salunkhe. Overview on Software Used in Pharma Industry. Int. J. Pharm. Sci. Rev. Res., 61(1), March - April 2020; Article No. 09, Pages: 52-58, ISSN 0976 – 044X [4] Hoffmann A, IGihny-Simonius J, Marcel Plattner, Vanja Schmidli-Vckovski , Kronseder e C “Computer system validation: An overview of official requirements and standards” Pharm [5] Jukka R, Johannes K “Review The Future of Pharmaceutical Manufacturing Sciences” Journal Of Pharmaceutical Sciences 104:3612–3638, 2015 Published online 2015 August 17 in Wiley Online Library (wileyonlinelibrary.com) [6] Madsen Ulf, KrogsgaardLarsen, Povl; Liljefors, Tommy (2002). Textbo ok of Drug- Design and Discovery, Washington, DC: Taylor & Francis [7] Ecemis M I, Wikel J H, Bingham C, Eric Bonabeau. A drug candidate design environment using evolutionary computation, Presented at IEEE Trans Evolutionary Computation, 12(5), 2008, 591-603 [8] http://www.softpedia.com/ [9] Software(PharmacyManagement)PharmacyMarketplace,http://www.pha rmacychoice.com/marketplace/cat egory.cfm/listing/Pharmacy_Manage ment_Software. [10] https://autodock.scripps.edu/ [11] https://www.simulations-plus.com/software/gastroplus/ [12] Patel, J.R.; Joshi, H.V.; Shah, U.A.; Patel, J.K.A Review on Computational Software Tools for Drug Design and Discovery. Indo Global J. Pharm. Sci., 2022; 12:53-81. DOI: http://doi.org/10.35652/IGJPS.2022.12006. [13] Mannam A, Mubeen H “Review Article Digitalisation And Automation In Pharmaceuticals From Drug Discovery To Drug Administration” international Journal of Pharmacy and Pharmaceutical Science 10(6), 2018 May 8, 1-10 [14] Saini, J.P., Thakur, A., & Yadav, D. (2025). AI-driven innovations in pharmaceuticals: Optimizing drug discovery and industry operations. RSC Pharm., 2, 437-454. [15] Uriti, S. V. (2025). A review on progress and potential of machine learning and AI in pharmaceutical development. Journal of Pharma Insights & Research, 3(2), 019-030. [16] Sultana, A., Maseera, R., Rahamanulla, A., & Misiriya, A. (2023). Emerging of artificial intelligence and technology in pharmaceuticals: review. Future J. Pharm. Sci., 9, 65. [17] Lee, S.L., O’Connor, T.F., Yang, X. et al. (2015). Modernizing Pharmaceutical Manufacturing: from Batch to Continuous Production. Journal of Pharmaceutical Innovation, 10(3), 191–199. [18] Niu, Z., Zhang, L., & Li, Y. (2022). Applications of Artificial Intelligence in Regulatory Science: Opportunities and Challenges. Clinical and Translational Science, 15(6), 1328–1340. [19] Harpaz, R., DuMouchel, W., LePendu, P., Bauer-Mehren, A., & Shah, N. H. (2013). Performance of Pharmacovigilance Signal-Detection Algorithms for the FDA Adverse Event Reporting System. Clinical Pharmacology & Therapeutics, 93(6), 539–546.

Copyright

Copyright © 2025 Shubham Mishra, Mr. Pramod Mishra, Mr. Sujeet Pratap Singh, Dr. Tarkeshwar Prasad Shukla. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.